Skip to main content
. 2022 Apr 30;10(5):1047. doi: 10.3390/biomedicines10051047

Figure 2.

Figure 2

Pre-operative levels of soluble immune-checkpoints (sPD-1, sPD-L1, sB7.2, sCD25, sLAG3, sTim3 and s4-1BB) in lung cancer patients who suffered or not from disease relapse. (A) sPD-1 levels in plasma samples from LC patients. (B) sPD-L1 levels in plasma samples from LC patients. (C) sB7.2 levels in plasma samples from LC patients. (D) sCD25 levels in plasma samples from LC patients. (E) sTim3 levels in plasma samples from LC patients. (F) s4-1BB levels in plasma samples from LC patients. (G) sLAG3 levels in plasma samples from LC patients. Differences between patients were analysed by either Mann–Whitney U test; **** p < 0.0001 (A,B,D–G) or Unpaired t-test (C).